Top Page | English | 简体中文 | 繁體中文 | 한국어 | 日本語
  Press Releases
Tuesday, September 17, 2024
LENVIMA(R) (lenvatinib) Plus KEYTRUDA(R) (pembrolizumab) in Combination With Transarterial Chemoembolization (TACE) Significantly Improved Progression-Free Survival Compared to TACE Alone in Patients With Unresectable, Non-Metastatic Hepatocellular Carcinoma (HCC)
Thursday, September 5, 2024
Eisai Accelerates Progress in Oncology Research with New Data at ESMO Congress 2024
Monday, September 2, 2024
Eisai Announces Status Relating to Acquisition of Own Shares
Thursday, August 22, 2024
Leqembi (lecanemab) Authorized for Early Alzheimer's Disease in Great Britain
Wednesday, August 14, 2024
"LEQEMBI" (Lecanemab) Approved for the Treatment of Alzheimer's Disease in the United Arab Emirates
Tuesday, August 6, 2024
Eisai: Update Regarding the Regulatory Status of LEQEMBI Subcutaneous Formulation
Wednesday, July 31, 2024
New Clinical Data Demonstrates Three Years of Continuous Treatment with Dual-Acting LEQEMBI (lecanemab-irmb) Continues to Significantly Benefit Early Alzheimer's Disease Patients Presented at AAIC 2024
Monday, July 29, 2024
Update on Regulatory Review of Lecanemab for Early Alzheimer's Disease in the European Union
Thursday, July 25, 2024
Eisai and EcoNaviSta Enter into Business Alliance Agreement Aimed at Building a Dementia Ecosystem and Commence Collaboration
Tuesday, July 23, 2024
Eisai to Present Dual-Acting Lecanemab Three-Year Efficacy and Safety Data and Discuss Long-Term Outcomes of Continued Treatment at the Alzheimer's Association International Conference 2024

Copyright © 2024 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 214 890 4418 | China: +86 181 2376 3721 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575

Connect With us: